Sign in

NOUS-209 neoantigen vaccine & Colorectal cancer

Last updated: 19 Nov 2026 incl. AI

Sources: PubMed, ClinicalTrials.gov, Journal for ImmunoTherapy of Cancer, Journal of Clinical Oncology

Does NOUS-209 neoantigen vaccine treat colorectal cancer?

Checked

Posts say that a vaccine called NOUS-209 can help prevent or treat colorectal cancer.

It is not proven that NOUS-209 neoantigen vaccine treats colorectal cancer. 4 new studies in people are running or will start soon, say the trial registers.

What studies show

As of , no study proves that NOUS-209 neoantigen vaccine treats colorectal cancer. We found 44 published papers on NOUS-209 neoantigen vaccine and colorectal cancer. They were published between 2016 and 2026. 4 of them are studies in people. At least 69 people took part. None of them was a fair test in which chance decided who got it and who did not. 15 were studies in animals, and 2 were only in cells in the lab. 5 papers are reviews that sum up other studies.

Trials in people

The first small test in people, mainly to check safety, included 45 people with Lynch syndrome. Lynch syndrome is an inherited condition that raises the risk of bowel and other cancers. No group got a dummy treatment for comparison. The test looked at safety and immune response, not at whether cancer was prevented. The authors report no serious side effects linked to the vaccine. All 37 people whose immune response could be checked showed a response to the vaccine.

Other studies in people

Other vaccines made for each patient were tried in people with advanced bowel cancer. One study of 6 people found immune responses in about 2 in 3, with no comparison group. Another test of a different vaccine reported it was safe, with longer survival in some people.

Reviews

Reviews say vaccines might one day help prevent or treat bowel cancer. They may work best after surgery, and perhaps better with other immune drugs.

In animals

Studies in mice tested other vaccines, not NOUS-209, against bowel cancer. The authors report slower tumour growth and longer survival. Results in animals do not always hold in people.

In the lab

Lab work on a different vaccine found immune responses in mice and monkeys.

Other papers

One person given NOUS-209 with another drug had polyps shrink and no cancer left in the removed tumour. That person also had surgery and another drug, so this does not show the vaccine caused it.

What this means for you

Our verdict: Unproven.

NOUS-209 looked safe and caused an immune response in a small test in 45 people. That test did not check whether cancer was prevented, and no compared test has been done.

Do not stop or change your treatment because of a story about NOUS-209 neoantigen vaccine. A study in people is not proof that it helps you. If you are thinking about NOUS-209 neoantigen vaccine, talk to your care team first.

This page explains what research has found so far. It is not medical advice. Talk to your doctor before you start, stop or change any treatment.

We searched 18 scientific databases for research from the last 10 years (since 17 Nov 2016).

Sources

  1. A Vaccine (Nous-209) for the Reduction of Colorectal Lesion Size in Patients With Lynch Syndrome. 2027. Study in people. ClinicalTrials.gov
  2. Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial. Nat Med 2026. Study in people. PubMed
  3. Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report. J Immunother Precis Oncol 2026. Other paper. PubMed
  4. Mutations Targeted by Nous-209 Immunotherapy Occur Early in Lynch Syndrome Carriers' Precancer Lesions with Microsatellite Instability. Cancer Prev Res (Phila) 2026. Other paper. PubMed
  5. Personalized Neoantigen Vaccine plus Regorafenib Increases Rgs2⁺CD8⁺ T Cells Infiltration and Reprograms the Tumor Microenvironment in Microsatellite Stable Colorectal Cancer Liver Metastases. Adv Sci (Weinh) 2025. In animals. PubMed
  6. Targeting B7-H3 enhances the efficacy of neoantigen-based cancer vaccine in combination with radiotherapy. NPJ Vaccines 2025. In animals. PubMed
  7. 638 Nous-209 vaccine induces shared neoantigen immunogenicity for cancer interception in healthy lynch syndrome carriers: results from phase Ib/II trial. Journal for ImmunoTherapy of Cancer 2024. Other paper. Journal for ImmunoTherapy of Cancer
  8. Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer. Cancer Immunol Immunother 2023. Study in people. PubMed
  9. Cancer Vaccines: From the State of the Art to the Most Promising Frontiers in the Treatment of Colorectal Cancer. Pharmaceutics 2023. Review. PubMed
  10. Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer. Journal of Clinical Oncology 2023. Other paper. Journal of Clinical Oncology
  11. Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients. 2022. Study in people. ClinicalTrials.gov
  12. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med 2022. Study in people. PubMed
  13. Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines. Front Immunol 2021. Review. PubMed
  14. Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine. JCI Insight 2019. In the lab. PubMed
  15. Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions. Expert Rev Clin Immunol 2017. Review. PubMed

Frontlight Community

Share what you saw, tried or were told about this claim, and read what others went through. Posts are not medical advice: ask your doctor about your own treatment.

Be the first to share your experience or your question about this claim

Research you can look at next

Open trials and published studies linked to this claim, each with its source and date.

Questions to ask your doctor about colorectal cancer

This page explains what research has found so far. It is not medical advice. Talk to your doctor before you start, stop or change any treatment.

More checked claims